CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy

Children's National Medical Center, George Washington University, Washington, DC, USA.
Muscle & Nerve (Impact Factor: 2.28). 08/2011; 44(2):174-8. DOI: 10.1002/mus.22047
Source: PubMed


Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle.
We performed an open-label, "add-on" pilot study of CoQ10 in thirteen 5-10-year-old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score.
Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 μg/ml) were shown to be subject- and administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5% increase in muscle strength (P = 0.03).
Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD.

Download full-text


Available from: Ksenija Gorni, Sep 29, 2015
56 Reads
Show more